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Gómez-Benlloch, Daniel Porta-Casteràs, Marta Carulla-Roig, Anton
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• MDD participants have smaller GMV than HC in cerebellum and the frontal operculum 
• ANX participants have less GMV than HC in temporal gyrus and pars orbitalis 
• PTSD participants have smaller GMV in lingual gyrus and superior frontal gyrus 
• As patients age, GMV reductions are more pronounced in fronto-temporal regions 
• Higher proportion of females are related with GMV diminutions in temporal areas 
 
ABSTRACT 
The high comorbidity of Major Depressive Disorder (MDD), Anxiety Disorders (ANX), and Posttraumatic Stress Disorder (PTSD) has 
hindered the study of their structural neural correlates. The authors analyzed specific and common grey matter volume (GMV) 
characteristics by comparing them with healthy controls (HC). The meta-analysis of voxel-based morphometry (VBM) studies 
showed unique GMV diminutions for each disorder (p<0.05, corrected) and less robust smaller GMV across diagnostics (p<0.01, 
uncorrected). Pairwise comparison between the disorders showed GMV differences in MDD versus ANX and in ANX versus PTSD. 
These results endorse the hypothesis that unique clinical features characterizing MDD, ANX, and PTSD are also reflected by 









Keywords: Major depressive disorder, Anxiety disorders, Posttraumatic stress disorder, Comorbidities, Gray matter volume, Meta-
analysis, Structural neuroimaging, Neuropsychiatry 
 
1. Introduction 
Major depressive disorder (MDD), anxiety disorders (ANX) and posttraumatic stress disorder (PTSD) display 
a range of both overlapping and distinctive epidemiological and clinical features. From an epidemiological 
perspective, MDD and ANX are the most frequent mental disorders, being highly prevalent in the general 
population, and with comorbidity levels higher than expected by chance (Kessler et al., 2008, 2005). Likewise, 
MDD is the psychiatric comorbidity most commonly associated with PTSD (Rytwinski et al., 2013), a 
diagnosis that has been moved from the anxiety disorders category to the stress-disorder group in current 
diagnostic manuals (Diagnostic and Statistical Manual of Mental Disorders 5th Edition; DSM-5). 
Similarly, their phenotype is characterized by a high presence of negative emotional states (Eysenck and 
Fajkowska, 2018), distress, cognitive biases (Byllesby et al., 2016) and rumination. They also share prominent 
avoidance behaviors, which are linked with the development and maintenance of ANX and PTSD and also 
mediate subsequent progression to MDD (Struijs et al., 2018). Neurobiologically, they share a complex 
hereditary predisposition involving genes typically related to monoamine systems, neuropeptides and 
hypothalamus-pituitary-adrenal (HPA) axis, which in turn modify normal stress responses (Smoller, 2016).  
When focusing on the brain, neural correlates in structural magnetic resonance imaging (sMRI) have been 
regularly found in the three disorders, including lower grey matter volume (GMV) in the anterior cingulate 
(ACC)(Emre Bora et al., 2012; O’Doherty et al., 2015; Radua et al., 2010) and insular cortices (Bromis et al., 
2018; Radua et al., 2010; Sprengelmeyer et al., 2011). Indeed, the most recent meta-analysis of functional 
neuroimaging in mood and anxiety disorders described differences versus healthy controls in brain activity -
located in negative valence systems- shared across these disorders (Janiri et al., 2020a). However, each of 
them has specific and predominant symptom expressions, like sadness and apathy in MDD, worry and fear in 










identification of such disorder-specific correlates is particularly difficult as sMRI studies rarely exclude 
comorbidities and lower GMV in key regions such as ACC and insula appear to be a general marker of 
psychopathology (Goodkind et al., 2015). The few sMRI studies comparing MDD and ANX have pointed to 
potential differences in fronto-temporal regions (Lai and Wu, 2015; van Tol et al., 2010; Zhao et al., 2017), 
which have also demonstrated higher accuracy than clinical questionnaires distinguishing generalized anxiety 
disorder (GAD) from MDD using machine learning approaches (Hilbert et al., 2017). 
Given the above notions, the considerable amount of literature studying brain structure in these disorders and 
the necessity to measure their reproducibility, it is suitable to perform a meta-analysis of grey matter VBM 
(Ashburner and Friston, 2000) studies of MDD, ANX and PTSD. Samples will include non or minimal 
percentages of comorbidities in order to delineate their common and specific neural underpinnings. Specific 
neural correlates were studied looking at these disorders independently versus healthy controls (HC) and 
trough their direct comparison  
We hypothesized that common GMV reductions would overlap across disorders in key cognitive and 
emotional brain networks including cortical areas such as insula and cingulate gyrus, and also subcortical 
limbic structures such as hippocampus and amygdala (Janiri et al., 2020b; Logue et al., 2018; Sha et al., 2019). 
We also expected to find more prominent GMV reductions in prefrontal cortices (i.e. dorsolateral, orbitofrontal 
or ventromedial) in MDD (Bora et al., 2012; Wise et al., 2016; Wu et al., 2019). Regarding ANX disorders, 
PTSD has been included in the analyses until a few years ago, and there are no studies analyzing ANX 
disorders as they are conceptualized today in the DSM-5. However, based on proposed brain networks and 
recent studies on specific anxiety disorders, we expected to find GMV differences versus HC in regions 
included in fronto-parietal or/and ventral attention networks (i.e. ventrolateral PFC and temporo-parietal 
junction, Sylvester et al., 2012). Finally, based on a recent review of MRI findings in PTSD and a study using 
machine learning classification methods (Kunimatsu et al., 2020; Zilcha-Mano et al., 2020), we expected 










putatively in the basal ganglia, as the structures with a greater amount of evidence potentially overlap across 
disorders (i.e. prefrontal cortices, hippocampus, amygdala, anterior cingulate or insula). 
2. Methods and materials 
2.1. Literature Search 
An extensive search of structural VBM studies comparing subjects with MDD, ANX and PTSD disorders with 
HC was conducted in PubMed, Web of Knowledge, Science Direct and Scopus databases (Figure 1). The 
search keywords were [Title/Abstract]: morphometry OR voxel-based OR voxel-wise AND depression OR 
anxiety disorder OR panic disorder OR agoraphobia OR phobia OR stress disorder OR posttraumatic stress 
disorder AND "1998"[Date - Publication]: "2020/01/17"[Date - Publication]. Studies were included if: 1) 
performed whole-brain analysis, 2) included a comparison between patients with MDD/ANX/PTSD disorders 
and HC, 3) participants’ age was above 18 and below 65, 4) provided the t-map or coordinates in Montreal 
Neurological Institute [MNI] or Talairach space, 5) samples were free of any comorbid neurological conditions 
and 6) samples of patients had no or minimal current comorbid psychiatric disorders. In order to find the most 
optimal balance between excluding samples with any comorbidity (as they may be then non representative) 
and including highly comorbid samples, the maximum rate of current comorbidity with MDD/ANX/PTSD 
diagnosis was set at 25%. The percentage of studies not reporting comorbidities was 18.7 (18% for MDD, 8% 
for ANX and 30% for PTSD. If a sample was used in several studies, only the larger one was included. 
Similarly, only baseline data of longitudinal studies was incorporated. Manuscripts were included from 1998 
for MDD (first VBM study in MDD, (Shah et al., 1998)) and from 2003 for anxiety disorders(Massana et al., 
2003) and PTSD(Yamasue et al., 2003) until 17th January 2020. See Table 1. 
2.2. Data Extraction 
Relevant data for the studies were retrieved by six authors -all investigators- (MSB, EV, AG, DPC and MC) 
and then compared by MSB, EV, AG and DPC in order to minimize interpretation and data entry errors. 










The corresponding authors (or the principal in case of no response) of all studies meeting inclusion criteria 
were contacted via e-mail and asked for their original (t-maps) and/or relevant missing data of the manuscript. 
2.3. Differences in Demographic Variables 
We combined the age means and standard deviations and the proportion of males of the samples and applied 
ANOVA/ꭓ2 tests on the resulting statistics to explore potential demographic differences between MDD, 
ANX, and PTSD patients (R Stats Package version 4.0, https://www.r-project.org/). Please see the Supplement 
methods for details on the specific formulas used. 
2.4. Differences in Grey Matter Volume 
2.4.1. Global Differences  
We assessed the differences in global GMV using the function “Globals” from SDM-PSI (see below), which 
conducts a random-effects meta-analysis. 
2.4.2. Regional Differences  
To investigate grey matter volume regional differences we used the Signed Differential Mapping with 
Permutation of Subject Images (SDM-PSI, https://www.sdmproject.com/) version 6.21 (Albajes-Eizagirre, 
2019; Radua et al., 2014, 2012), the newest version of a meta-analytical neuroimaging method successfully 
used in many published meta-analyses. Some new features in SDM-PSI include a familywise correction for 
multiple comparisons using the Freedman-Lane procedure for its optimal statistical properties, and threshold-
free cluster enhancement (TFCE, (Smith and Nichols, 2009)) statistics. SDM-PSI also includes an almost 
unbiased estimation of effect sizes based on MetaNSUE algorithms, which use maximum likelihood 
estimation and conduct repeated leave-one-out jackknife procedures to avoid the possibility that a single or 











We conducted seven main meta-analyses, namely 1) all patients versus HC, 2) patients with MDD versus 
patients with ANX, 3) patients with MDD versus patients with PTSD, 4) patients with ANX versus patients 
with PTSD, 5) patients with MDD versus HC, 6) patients with ANX versus HC, and 7) patients with PTSD 
versus HC. All meta-analyses were run combining peak coordinates of each sample or original t-maps if 
provided. The MDD vs HC meta-analysis was replicated I) without including the 6 MDD t-maps to explore 
the effect of raw and unbiased data inclusion (rather than solely using the coordinates provided by the authors) 
in neuroimaging meta-analyses and ii) without including remitted patients in order to explore potential effects 
of having an active MDD episode. Finally, we used meta-regression to understand the potential contribution 
of age and sex to all patients' neural correlates altogether. Psychotropic medication was meta-regressed in all 
patients as well as for each psychiatric condition separately. For the MDD samples, meta-regressions were 
used to explore the effects of illness duration (in years) and depression severity in GMV. Depression severity 
was mostly measured through the Hamilton Depression Rating Scale 17. For studies reporting Montgomery-
Åsberg Depressing Rating Scale (MADRS) scores, we converted them to HDRS-17 equivalents (HDRS-17=-
1.58+0.86*MADRS, 33). We explored potential publication bias of each cluster peak of statistically 
significant clusters via funnel plots and Egger’s test. 
We first set the statistical threshold at p<0.05 TFCE corrected with a minimum cluster size of 10 voxels. Later, 
we explored a more relaxed one (p<0.01, uncorrected), choosing only those clusters exceeding 50 voxels. In 
the case of the meta-analysis including all patients vs. all controls, smaller clusters were accepted giving the 
probable high levels of heterogeneity. In order to ease future replication analyses, we have generated an online 
database (available upon request) with all the clinical and methodological data from every study included in 
this meta-analysis. 
3. RESULTS 
3.1. Included Studies  
The search retrieved 3482 studies potentially suitable (Figure 1), from which finally 73 met all the inclusion 










2015) and the anxiety sample with highest reported MDD comorbidity was 24% (Irle et al. 2014). For PTSD, 
the proportion of comorbid cases was zero or not reported in three studies. All studies used parametric 
approaches, except for Koolscijn et al., 2010, Tavanti and colleagues (2012), Lai et al., (2012 and 2015), 
Rodriguez et al., 2014 and Lai et al. (2014 and 2015). A total of 7 original t-maps were achieved (MDD=6, 
ANX=1). See Table 1 for more detailed information. 
3.2. Sample Characteristics 
MDD meta-analysis included 45 studies with 53 MDD independent datasets. When the MRI was performed, 
145 patients (7.77%) were in remission and 1721 (92.23%) had an acute MDD episode. The mean score of the 
HDRS-17 was 2.07 for those patients in remission and 20.62 for those in an acute episode. Of the studies 
reporting psychotropic medication use, 47.21% of patients were taking at least one or more antidepressants at 
the time of the scanning. ANX meta-analysis included a total of 20 studies with 22 independent datasets. Of 
the 617 participants, 237 were diagnosed with panic disorder (PD, 38.4%), 234 with social anxiety disorder 
(SAD, 37.9%), 59 with GAD (9.6%), 59 with specific phobia (SP, 9.6%), 10 with panic disorder with 
agoraphobia (PDA, 1.6%) and 23 with comorbid anxiety disorders (2.76%). Of the studies reporting 
medication use, 9.6% were taking antidepressants or/and anxiolytics. For more detailed information of the 
studies included see Table 1). 
3.3. Age and gender differences 
3.3.1 Major Depression Versus Anxiety Disorders: patients with ANX diagnosis (age=33.09+/-11.02; 41.7% 
males) were younger (d=0.39, t=8.47, p<0.001) than those with MDD (age=38.04+/-13.07; 38.1% males) but 
had a similar proportion of men and women (X2=2.38, p=0.123,). Age was then included in the MDD vs ANX 
meta-analysis as covariate. 
3.3.2. Major Depression Versus Post-Traumatic Stress Disorder: There were no differences regarding age 










proportion of males (X2=20.47, p<0.001) than those with MDD. Sex was then included in the MDD vs PTSD 
meta-analysis as covariate. 
3.3.3. Anxiety Disorders Versus Post-Traumatic Stress Disorder: There were significant differences regarding 
age (d=-0.31, t=-3.80, p<0.001) and sex proportion (X2=9.96, p=0.002), so both were included in the ANX vs 
PTSD meta-analysis as covariates. 
3.4. Differences in Grey Matter Volume 
3.4.1. Global Differences in Grey Matter Volume 
A total of 22 samples reported global GMV (13 MDD; 5 ANX and 4 PTSD). Individuals with MDD had lower 
global GMV compared to HC (Hedges g=-0.174, SE=0.059; z=-2.966; p=0.003, CI=-0.289—0.059) with low 
heterogeneity (τ<0.001; Q=10.590; df=12 and p=0.564). There were no global GMV differences between 
ANX and HC (Hedges g=0.092, SE=0.116; z=0.795; p=0.426, CI=-0.135—0.320) with no heterogeneity 
(τ<0.001; Q=4.540; df=4 and p=0.338), or between PTSD and HC (Hedges g=-1.226, SE=0.964; z=-1.271; 
p=0.203, CI=-3.116—0.664) with significant levels of heterogeneity (τ<3.540; Q=47.725; df=3 and p<0.001). 
After performing a sensitivity analysis, it was observed that the study from Tavanti and colleagues (2012) 
drove the heterogeneity levels (τ<0.000; Q=1.623; df=2 and p<0.444), although the lack of GMV differences 
persisted (Hedges g=-1.375, SE=0.210; z=-1.787; p=0.08, CI=-0.786—0.036). See Figure 2.  
3.4.2. Regional Differences in Grey Matter Volume 
3.4.2.1. MDD Versus HC analysis: There were two clusters showing significant GMV reductions in patients 
with MDD compared to HC in the bilateral cerebellum and in the left inferior frontal gyrus (IFG). When 
applying a more liberal threshold (p<0.01, uncorrected), the volume reductions extended to the right IFG 
including bilateral insula, left superior frontal gyrus (SFG) including anterior cingulate subregions and right 
ventromedial prefrontal cortex, bilateral hippocampi and left rolandic operculum including right posterior 










more detailed information about the cluster’s statistics, heterogeneity and publication bias see Table 2 (TFCE 
p<0.05) and Supplementary Table 1 (p<0.01, uncorrected). 
3.4.2.1.1 MDD Versus HC analysis (excluding t-maps): When excluding the 6 original MDD t-maps (Figure 
4), the brain region showing the largest GMV reduction was the left insula extending to the rolandic operculum 
and the IFG. When applying a more liberal threshold (p<0.01, uncorrected), regions were then more similar 
to those appearing in the analysis including the t-maps (right SFG extending to anterior cingulate and right 
ventromedial prefrontal cortex). Patients with MDD did not show regional GMV increases with respect to HC 
(Supplementary Table 2). 
3.4.2.1.2 MDD Versus HC analysis (excluding remitted patients): When excluding remitted patients 
(Supplementary Table 3), the brain region showing the largest GMV reduction were the left inferior frontal 
gyrus (BA 48) and the left hippocampus (BA 20). When applying a more liberal threshold (p<0.01 
uncorrected), GMV of patients were smaller in bilateral cerebellum, bilateral insula, right gyrus rectus (BA 
11), right hippocampus (BA 20), right superior frontal gyrus (BA 8 and 11), right heschl gyrus (BA 48), left 
ACC (BA 32), right middle frontal gyrus (BA 46) and left angular gyrus (BA 22). Patients with acute MDD 
did not show regional GMV increases with respect to HC. 
3.4.2.2. ANX Versus HC analysis: Patients with ANX had significantly smaller GMV than HC in left STG 
extending to IFG (Table 2). When relaxing the threshold (Supplementary Table 1), GMV reductions 
appeared in left orbitofrontal and dorsolateral prefrontal gyri (BA 10), in the bilateral paracingulate gyrus (BA 
24) and in bilateral insula.  Patients with ANX did not show regional GMV increases with respect to HC. 
Results are shown in Figure 3B. 
3.4.2.3. PTSD Versus HC analysis: Patients with PTSD showed smaller GMV than HC in left lingual gyrus 
extending to fusiform gyrus and in the bilateral SFG (BA 8) as shown in Table 2. When applying a more 
liberal threshold (see Supplementary Table 1), left post central gyrus, right fusiform gyrus, left calcarine 










3.4.2.4. MDD vs ANX analysis: The bilateral cerebellum and the superior temporal gyrus (STG) differentiated 
the MDD and ANX groups, with patients with ANX (compared to HC) displaying smaller temporal volumes 
and patients with MDD pronounced smaller cerebellar volumes (Table 3, Figure 3D). 
3.4.2.5. PTSD Versus ANX analysis: Participants with ANX showed less GMV in BA 48, including rolandic 
operculum, right STG and right insula when compared to HC than participants with PTSD. Also, participants 
with PTSD showed smaller GMV in left fusiform gyrus extending to lingual gyrus and cerebellum (BA 18) 
(Table 3, Figure 3E). 
3.4.2.6. PTSD Versus MDD analysis: There were no significant differences at any explored threshold between 
PTSD and MDD, covarying by sex.  
3.4.2.7. Conjunction analysis (MDD, ANX and PTSD vs HC): The conjunction analysis did not show 
significant results at p<0.05, TFCE corrected. When applying a more liberal threshold (p<0.01, uncorrected), 
a cluster of reduced GMV in the left middle cingulate cortex (MCC), (Supplementary Table 4, Figure 3F) 
appeared. There were no regions of larger volume in patients compared to HC at any threshold. 
3.5. Meta-regressions 
Meta-regression analyses of age and sex (Supplementary Table 5) indicated that studies with older patients 
(altogether) had smaller volumes relative to HC in the superior temporal gyrus (BA 38 and 48, including the 
insula and the rolandic operculum) and in the middle temporal gyrus (BA 20). Those studies with bigger 
proportion of women found smaller grey matter volume compared with HC in left insula extending to left 
rolandic operculum, left heschl gyrus, left putamen and also in the right inferior, middle and STG (BA 20, 21 
and 22 respectively) and the left middle temporal gyrus (BA 21). Studies including participants with longer 
MDD duration reported less GMV in the right fusiform gyrus extending to the parahippocampus (BA 37) and 











Finally, those samples with higher proportion of medicated patients (Supplementary Table 6) showed lower 
GMV in the bilateral angular gyrus (BA 39), right middle occipital gyrus (BA 39), right middle temporal gyrus 
(BA 20), right hippocampus, right dorsolateral and middle PFC (BA 9) and left ACC (BA 11). When analyzing 
the effect of medication separately for each disorder, those MDD samples with higher proportion of medication 
showed lower GMV in bilateral ACC (BA 11), those samples with patients with ANX in bilateral insula and 
in right rolandic operculum (BA 48), and those patients with PTSD exhibited a positive relationship between 
GMV and medication intake in left inferior parietal gyri (BA 39, 40 and 7), right angular gyrus (BA 39), right 
inferior parietal gyri (BA 40) and right middle occipital gyrus (BA 19). 
3.6. Publication Bias and Heterogeneity Tests  
All results reported in meta-analyses and meta-regressions were nonsignificant in the Egger tests (p>0.05), 
suggesting no publication bias. Also, the I2-statistic percentages ranges between 0 and 40%, which is 
considered irrelevant regarding heterogeneity (Deeks et al., 2020). 
4. Discussion 
This is the first meta-analysis providing a quantitative evaluation of GMV alterations across MDD, ANX and 
PTSD and including information both from reported coordinates and original t-maps. The findings showed 
disorder-specific GMV reductions in fronto-limbic and cerebellar regions in MDD, fronto-temporal in ANX 
and fronto-occipital in PTSD. These findings replicate and extend the findings of previous studies and provide 
a much-needed summary of an often disparate literature that is difficult to integrate. 
Contrary to what it was hypothesized based on prior research, there are not statistically significant 
structural brain correlates overlapping across disorders (Goodkind et al., 2015). Although Goodkind et al. was 
cited to support the hypothesis of a transdiagnostic marker of psychopathology, they do not include the PTSD 
category and instead included schizophrenia, bipolar disorder, OCD, or substance abuse patients, partly 
explaining the lack of replication in the current meta-analysis. In any case, what they do report as common 
neurobiological substrates are bilateral insulae and dorsal ACC. Insula has shown smaller volumes in many 










level), thus supporting its presence as a transdiagnostic marker for mood and anxiety disorders. On the other 
hand, the region that has appeared when lowering the statistical threshold (<0.01, uncorrected) in the common 
meta-analysis (mid-cingulate cortex) is in line with the widely reported role of this corticolimbic structure in 
mood, anxiety, and trauma-related disorders. In fact, the mid-cingulate region may represent a hub for various 
brain circuits as it is involved in numerous functions including a cognitive role in decision making, response 
initiation in the context of free choice, selective/divided/oriented attention, conflict monitoring or encoding 
reward values (Vogt, 2016). More specifically, MCC has been associated with avoidance (Hayes et al., 1996) 
and cognitive reappraisal or emotion suppression (Picó-Pérez et al., 2017), which are regulation strategies 
identified to be disturbed in those patients. Indeed, this cingulate sub-region has been found to play a key role 
when training emotion regulation in healthy participant’s trough neurofeedback (Cohen Kadosh et al., 2016) 
and to be involved in pain and fear processing (Vogt et al., 2003), so it may be related to the common 
etiopathogenic factors and shared clinical characteristics of these conditions. In any case, this result should be 
taken cautiously as did not surpass the FWER correction.  
The results of the MDD meta-analyses consolidate the previously described prefrontal alterations but 
mostly highlight the relevance of the cerebellum in MDD. Probably due to the modest understanding of the 
cerebellum emotional and cognitive processes, this structure has often been overlooked and less discussed in 
psychiatric neuroimaging studies. However, a non-negligible part of the cerebellum is linked with affective, 
cognitive and self-referential functions  and participates in functional networks of information processing 
(Klein et al., 2016); cerebellar GMV reduction have been linked with persistence of cognitive deficits in MDD 
patients (Depping et al., 2020). This relationship between GMV cerebellar reduction and symptom persistence 
might also underlie our finding of an association of such reductions and illness duration in MDD. While those 
structures do not coincide with the few reported to date, the extended use of ROIS in longitudinal studies (of 
the hippocampus) together with other methodological differences, makes it difficult to draw conclusions now. 
It is also worth noting that the latest mega- and meta-analytical research in MDD do not analyze volumetric 
differences in cortical structures, favoring cortical thickness and surface area, which could explain why our 










to truly elucidate the causality of the observed relation between illness duration and brain structure, more 
whole-brain longitudinal studies are needed. The current meta-analysis of patients with MDD vs HC has also 
confirmed the GMV reduction of cortical regions like the opercular part of the IFG and, with a wicker 
statistical significance, of the left insula and the anterior cingulate. Interestingly, prefrontal regions showing 
smaller volumes in MDD samples, have been linked to MDD prognosis (Belden et al., 2015; Fonseka et al., 
2018), providing more evidence of their potential value of reliable MDD biomarker. 
Anxiety disorder studies were characterized by a significantly greater GMV reduction in the left STG 
area when compared with MDD studies. Of the hypothesized altered circuits (Sylvester et al., 2012), GMV 
decreases in brain structures of the ventral attention network (VAN) show statistical significance. VAN 
network includes STG amongst other regions and is documented to play an important part in the orientation 
of the stimulus-driven attention. It has been hypothesized that a similar reorienting mechanism may mediate 
the shift from internally directed stimuli (i.e., worrisome thoughts) to environmental events, and that VAN 
may have a main role in this process. Thus, the present meta-analysis confirms the previous findings of reduced 
temporal and frontal gyrus in patients with anxiety disorders, and points toward a pronounced involvement of 
the left temporal pole. Also, when directly comparing ANX with PTSD, the former presented smaller volumes 
of the STG along with insula, rolandic operculum and anterior cingulate, which are areas closely related with 
the cingulo-opercular network (CON) network, which is the other neuronal circuit described to be altered in 
ANX (Sylvester et al., 2012). 
The meta-analysis comparing patients with PTSD to HC detected reductions of GMV in the left lingual 
and fusiform gyrus and with superior frontal gyrus (BA8). These structural findings are partially in line with 
a recent review of MRI studies in PTSD (Kunimatsu et al., 2020; Wang et al., 2020). Such divergence may be 
explained by the fact that first studies on PTSD were guided by the hypothesis of hippocampal involvement 
(due to its relationship with stress responses) and hence all research was highly focused on this structure. With 
most of the literature limited to certain ROIs, it seems easy to devote less attention to brain regions not included 
in initial operating hypothesis. Neuroimaging biomarker studies of brain structure have as well mainly focused 










when comparing PTSD against ANX, PTSD individuals presented with less GMV in fusiform gyrus, 
extending to lingual gyrus and cerebellum. Thus, these volume differences located in occipital regions might 
underlie key clinical differences between those disorders. The present meta-analysis of whole-brain studies 
brings back the focus on occipital and frontal regions and points (with weaker statistical power) to regions 
highly reported in PTSD neuroimaging research such as the middle cingulate and the parahippocampus. 
There are some limitations that are worth highlighting. First, as voxel-based meta-analyses are mostly 
based on summarized data (except for those cases in which original maps were available) it is likely to expect 
some imprecise results. In addition, despite VBM being a relatively consistent methodology, there are many 
analysis parameters, such as slice thickness, smoothing, statistical threshold, cluster based, standard space, 
correction and Jacobian modulation, which, although reported, are not possible to be considered in the analysis 
with current methodologies. Likewise, the covariates included are also heterogeneous as each study controls 
for age, sex, total intracranial volume or total GMV quite arbitrarily. Likewise, although some clinical 
characteristics have been considered (i.e., depressive symptomatology, illness duration or medication), factors 
such as the number of previous episodes or age of onset have not. Also, the fact that we focused mainly on 
non-comorbid diagnosis reduces the power in the comparisons versus HC, but conversely allowed us to draw 
strong conclusions about disorder specificity. In this regard, it should be noticed that, although 81% of the 
total sample explicitly reported no comorbidities, a 19% did not described such sample characteristic. 
Regarding the method employed, although it controls for false-positive results, false-negative results could not 
be completely ruled out. Related to this, the meta-analysis comparing all participants with a psychiatric 
diagnosis versus HC only reached significance with the more relaxed threshold, which leads to take this result 
with appropriate caveats and require to be replicated in future independent datasets. Finally, as recent clinical 
and imaging studies on psychiatric population suggest, using data-driven methods instead of only diagnosis 
guidance would allow studying heterogeneity within clinical populations. 
The current meta-analysis points to specific neural correlates for highly comorbid disorders such as 
MDD, ANX and PTSD: MDD was uniquely characterized by cerebellar and frontal GMV decreases, ANX by 










be taken prudently because of lower statistical significance, mid-cingulate cortex appears as the brain structure 
altered across MDD, ANX and PTSD, which is consistent with the struggle in stress coping experienced by 
the three disorders. 
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PTSD= 0  
ANX= NA  
34 31.5(12.4) 18/16 
Guo et al., 2014 44 27.52(8.6) 22/22 1.59(3.04) - 25.18(5.2) NA 0 44 29.39(6.7) 20/24 
Jung et al., 2014 50 
NR: 40.8(12.7) 
RE: 43(10.1) 
14/36 - - 
NR= 18.8(4.7) 
RE= 20.9(4.1) 









Kandilarova et al., 
2019† 
39 46.4(13.9) 13/29 10.8(8.89) 37.3(12.6) 23.45(-)* 77 0 42 42.6(13.7) 13/29 
Klauser et al., 2015† 27 35.02(9.7) 9/18 9.04(6.5) 26.04(9.4) Not reported 48 ANX= 14.8  33 34.71(9.9) 12/21 












0 28 32.07(9.3) 14/14 
Koolschijn et al., 2010 28 64.04(10.90) 0/28 7.79(1.5) - 14.18(-)* 60.1 0 38 61.89(11.1) 0/38 
Kroes et al., 2010 29 33.4(NA) 8/21 - - - 76 0 29 32.45(NA) 13/16 
Lai et al., 2014 38 36.57(5.5) 18/20 5.68(1.5) - 22.26(2.4) Drug-naïve 0 27 38.29(11.8) 12/15 
Lai et al., 2015 53 40.07(9) 25/28 0.42(0.1) - 22.43(2.3) Drug-naïve 0 54 40.38(10.5) 12/42 
Lee et al., 2011 47 46(9.1) 5/42 3.89(6.3) 42.11(-) 20.1(6.9) 62 NA 51 45.7(8.04) 5/46 
Leung et al., 2009 17 45.5(8.5) 0/17 7(4.1) - - 100 NA 17 45.8(9.8) 0/17 
Li et al., 2019 56 35.1(8.9) 20/36 1.1(1.3) - - Drug-naïve 0 56 30.7(8.0) 23/33 
Lu et al., 2019 30 23.95(5,3) 17/13 2.61(2.22) - - Drug-free 2 weeks 0 48 21.5(3.84) 18/30 











NA 17 24.24(4.4) 10/7 
Machino et al., 2013 29 39.57(8.3) 16/13 4.38(4.8) - 13.90(4.3) 97 NA 29 38.66(8.4) 16/13 
Mak et al., 2009 17 45.5(8.5) 0/17 - - - 100 0 17 45.8(9.8) 0/17 










Peng et al., 2010 22 46.7(8.9) 8/14 0.72(0.5) 45.98(-) 18.50(6.3) 23 0 30 45.9(9) 11/19 
Qi et al., 2014 18 31.06(7.4) 7/11 - - 22.28(3.3) Drug-free 6 months 0 28 28.61(5.5) 15/13 
Rodriguez et al., 2014† 32 48.68(13) 12/20 10.96(10.5) 37.71(13.7) 21.73(-)* 88 ANX= 9.4  64 46.03(9.8) 26/38 













0 107 36.2(10.3) 47/60 
Scheuerecker et al., 
2010 
13 37.9(10.1) 10/3 4.36(6) -  Drug-free 1 year 0 15 35.5(10.9) 10/5 

















0 32 46(8.3) 9/23 












NA 20 49.3(11.8)  13/7 
Shen et al., 2016 147 30.5(9.8) 50/97 8.49(7.5) 29.89(3.8) 23.83(4.8) Drug-naïve 0 130 30.09(7.1) 49/81 
Soriano-Mas et al., 2010 7  61.56(9.7) 29/41 10.45(10.1) 51.11(12.6) 28.60(7.6) 71 0 40 59.23(7.1) 17/23 
Tae et al., 2015 20 42.5(14) 0/20 9.5(11.3) 31.8(13.1) 21.7(8.7) Drug-free 3 months 0 21 42.3(10.2) 0/21 
Ueda et al., 2016 30 44.3(13) 17/13 - - 7,7(5.1) Drug-naïve NA 48 41.2(11.4) 35/13 
Van tol et al., 2010  68 37.16(10.2) 24/44 - 25.62(10.4) 9.61(-)* 26 0 65 40.54(9.7) 24/41 










Wagner et al., 2011 30 37.55(11.5) 5/15 5.95(6.8) 31.6(11.6) 20.08(-)* NA 0 30 35.1(10.4) 5/25 
Yang et al., 2017a 35 44.54(11.2) 0/35 2.69(0.8) 41.25(10.1) 28.29(8) Drug-free 6 months 0 23 39.09(14.4) 0/23 
Yang et al., 2017†b 84 30.88(7.84) 23/61 0.75(0.66) - 23.83(5.02) Drug-naïve ANX= 15.5  84 30.39(6.71) 23/61 
Yoshikawa et al., 2006 22 48(4.9) 0/22 - - - Drug-free 1 month 0 29 49(5) 0/29 
Zhang et al., 2009 15 33.5(10.2) 10/5 10.3(4.8) - 17.08(-)* 100 NA 15 33.4(10.2) 10/5 
Zhang et al., 2012 33 20.52(1.7) 17/16 - - - Drug-naïve 0 32 21.08(1.5) 17/15 
Zhao et al., 2017 37 26.7(7.1) 25/12 2(0.5) - 25(5.2) Drug-naïve 0 41 27.1(7.2) 26/15 
Zou et al., 2010 23 31.1(10.4) 10/13 0.63(0.4) 30.47(-) 24.4(3.9) Drug-naïve 0 23 36.6(12.9) 10/13 
  
ANXIETY DISORDERS DISORDERS (n=617) HEALTHY CONTROLS (n=602) 









Asami et al., 2009 24 37.03(10.2) 9/15 PD - - 
MDD= 12.5 





Cheng et al., 2015 20 23.3(3.7) 13/7 SAD 
SAD=6.2(4.8)
a 












Hayano et al., 2009 27 38.2(9.9) 10/17 PD - - 
MDD= 11.1  









Irle et al., 2014 67 31(10) 32/35 SAD 43(10)b 9 
MDD= 23.9 
PTSD= 0 
64 32(10) 33/31 








Liao et al., 2011 18 22.67(3.8) 12/6 SAD 
6.39(5)a / 
41.11(8.7)b 




Ma et al., 2019 21 34.92(9.48) 12/9 GAD 17.09(5.3)a 
Drug-free (>6 
month) 
0    













































































Yoo et al., 2005 18 33.3(7.1) 9/9 PD 8.7a - 0 18 32(5.8) 11/7 





























Sex (M, F) 




40(9) 10/9 75.8(21.8)d Drug-naïve 0 19 41(6) 15/4 
Chen et al., 2006 
1
2 











26.3(8.1) 21/9 10.9(2.3)a Drug-naïve 0 30 26.2(6.6) 21/9 












45.6(6.2) 0/14 - - 
MDD= 0  
ANX= NA  
100 47.1(5.7) 0/100 




35.9(NA) 9/15 30.39(14.4) 41.7 




















Footnote: SD=Standard Deviation, M=Male, F=Female, MDD= Major depressive disorder, HDRS= Hamilton depressive rating scale, cMDD=Current 
MDD, rMDD= remitted MDD, NR= Non-responder, RE=Responder, TRD= treatment-resistant depression, TSD= treatment-responsive depression, 
dMDD= depressed MDD, FE= first episode, Rem= remitted, Rec= recovered, PD=Panic disorder; PTSD= posttraumatic stress disorder, PDA=Panic 




dClinician Administered PTSD Scale (CAPS)  




28.9(4.2) 11/2 - Drug-naïve 0 15 30.1(6.3) 14/1 
Tan et al., 2013 
1
2 
37.6(3.7) 12/0 53.8(7.3)b Drug-free (>1 month) 0 14 40.8(5.2) 14/0 








Yamasue et al., 
2003 
9 44.6(16) 5/4 - - 0 16 44.4(14) 10/6 




40.8(6.8) 10/0 - - 
MDD= 0  
ANX= NA 










†Studies that provided original t-maps 












Table 2. Results of the brain volumes showing differences between MDD and HC (A), ANX and HC (B) and PTSD and HC (C) with TFCEb correction 
(p<0.05) 















R cerebellum, hemispheric lobule 
VIII 
 14,-60,-48 -4.452 0.001    
L cerebellum, hemispheric lobule 
VIIB 
 -36,-62,-46 -4.427 0.002    
L cerebellum, hemispheric lobule IX  -10,-60,-44 -3.900 0.003    
Cerebellum, vermic lobule IX  2,-60,-42 -3.894 0.003    
Cerebellum, vermic lobule VIII  -2,-64,-42 -3.886 0.003    
R cerebellum, crus II  36,-70,-44 -3.835 0.019    
R cerebellum, crus I  28,-82,-34 -3.622 0.024    
L inferior frontal gyrus, opercular 
part, BA 48 













B) ANX < HEALTHY CONTROLS        
L temporal pole, superior temporal 
gyrus 




L inferior frontal gyrus, orbital part  -36,22,-16 -4.922 0.017    
C) PTSD < HEALTHY CONTROLS        
TFCE corrected (p<0.05)b        




L fusiform gyrus, BA 18  -24,-70,-14 -4.196 <0.001    
L fusiform gyrus, BA 37  -30,-58,-16 -3.733 <0.002    




R superior frontal gryus, medial, BA 
8 
 5,28,50 -4.163 0.012    
Footnote: MDD= major depressive disorder, HC= healthy controls, ANX= anxiety disorders, PTSD= posttraumatic 
stress disorders, MNI=Montreal Neurological Institute, SDM= Signed Differential Mapping, p= p-value; I2= 
Percentage of variance attributable to study heterogeneity; L= left, R= right, BA= Brodmann area, unc= uncorrected p 
value. 
aExtracted from Hedges’ g value 






















Table 3. Results of the brain volumes showing common (A) and different (B, C, D) grey-matter differences in MDD, ANX and 
PTSD. Threshold-free cluster enhancement TFCE correction at p<0.05. 













A) Reductions in MDD, ANX and PTSD vs 
HC   
No suprathreshold clusters 
B) MDD < ANX*        




Cerebellum, vermic lobule, IV/V  0,-50,-6 2.267 0.002    
R cerebellum, hemispheric lobule VIII  18,-62,-50 2.194 <0.001    
        Cerebellum, vermic lobule XI  0,-60,-40 2.156 <0.001    
MDD > ANX*        
L temporal pole, superior temporal gyrus, 
BA 38 














        L temporal pole, superior temporal 
gyrus, BA 38 
 -50,12,-14 -2.942 <0.001    
        L superior temporal gyrus, BA 22  -58,-12,-4 -2.852 0.005    
        L rolandic operculum, BA 48  -46,-6,10 -2.228 0.005    
        L superior temporal gyrus, BA 48  -58,-6,0 -2.103 0.011    




C) PTSD vs MDD** No suprathreshold clusters 
D) PTSD > ANX***        




R rolandic operculum, BA 48  54,-2,8 3.096 <0.001    
R insula, BA 48  48, -6,6 2.923 <0.001    




L anterior cingulate / paracingulate gyri, BA 
10 


















L lingual gyrus, BA 18  -14,-62,-6 -2.419 0.012    
L cerebellum, hemispheric lobule VI, BA 
18  
 -16,-64,-16 -1.614 0.037    
 
Footnote: MDD= major depressive disorder, ANX= anxiety disorders, PTSD= posttraumatic stress disorder, MNI=Montreal 
Neurological Institute, SDM= Signed Differential Mapping; p=p-value; I2= Percentage of variance attributable to study 
heterogeneity, L= left, R= righ 
bExtracted from Hedges’ g value 
*Comparison including age as covariate 
**Comparison including sex as covariate 























Footnote: ROI=region of interests, SVC= small volume correction, VBM= voxel-based morphometry, 
MDD= major depressive disorder, ANX= anxiety disorders, PTSD= posttraumatic stress disorder  
* (34, 47, 48) 
 
Figure 2. Forest plots of the the mean (Hedge’s g) along with its corresponding z and P values,  the standard 
error (SE) and the confidence interval (CI) of global gray matter volume differences between patients with 
major depressive disorder (MDD), anxiety disorders (ANX) and post-traumatic stress disorder (PTSD) 
versus healthy controls (HC). 
 
Figure 3. (A) Results of meta-analysis between patients with MDD and HC. (B) Results of meta-analysis 
between patients with ANX and HC. (C) Results of meta-analysis between patients with PTSD and HC. (D) 
Results of meta-analysis between all patients and healthy controls (HC). (E) Results of meta-analysis between 
patients with MDD and patients with ANX. (F) Results of meta-analysis between patients with ANX and 











* Brain regions that reach p<0.05 TFCE correction in bold 
Foonote: MDD= major depressive disorder, HC= healthy controls, ANX= anxiety disorders; PTSD= 










inferior frontal gyrus, ACC= anterior cingulate cortex; MCC= middle cingulate cortex; SFG, superior frontal 
gyrus, PH= parahippocampal, CF= calcarine fissure, HG= heschl gyrus. Color bar indicates SDM z scores. 
 
Figure 4. Major depressive disorder versus healthy controls without t-maps  
Footnote: L=left, R=right, BA= Brodman area  
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